NSABP Members' Area   Password Protected - Access   Limited to NSABP Participating   Institutions Only NSABP Foundation, Inc. General NSABP Information   Financial Conflicts of      Interest Policy   Contact the NSABP   Employment Clinical Trials Information   Clinical Trials Overview   Protocol Chart   Never Say Lost Treatment Trials Information   Protocol B-51   Protocol B-52   Protocol B-53/S1207   Protocol B-55/BIG 6-13 Prevention Trials Information   Protocol P-1 - BCPT   Protocol P-2 - STAR To report problems, ask questions or make comments, please send e-mail to: Webmaster@nsabp.pitt.edu

Annotated Bibliography of NSABP Publications Technical Limitations of Sentinel Node Biopsy in Breast Cancer: A Single Surgeon's Experience Patel NA, Dusi D, Bragdon G, Julian TB The American Surgeon 2003 February;69(2)111-116 Abstract Few studies have attempted to critically identify patient- and tumor-related factors that limit sentinel node biopsy (SNB). These studies have been limited by sample size and surgeon variability. The present study attempts to enumerate these limitations in a unique group of patients. One hundred twenty-five SNBs performed by a single surgeon between May 1997 and June 2001 were reviewed. Overall SNB was successful in 96 per cent of patients with a 97 per cent correlation with the axillary node dissection. Sentinel node identification was not affected by age, tumor size, tumor location, prior segmental resection, or neoadjuvant therapy. No false negatives were noted in the neoadjuvant group. The use of blue dye alone significantly understaged patients when compared with isotope alone (P = 0.02). SNB is a highly accurate method to identify axillary metastases and its limitations are not affected by patient or tumor related factors. In the present study SNB detection by both isotope and blue dye has been shown to be superior to blue dye alone. This finding demonstrates that these limitations may be overcome with the standardization of the technique used.